UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab). The therapy becomes the first and only systemic treatment option in England for metastatic or local advanced cutaneous squamous cell carcinoma.
Libtayo has been jointly developed by the USA’s Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) for various oncology indications.
This means eligible patients will have full NHS access in England via routine commissioning. Around 28,000 people are diagnosed with CSCC every year, of which around 2% will be at risk of developing metastatic disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze